Barclays’s Fortress Biotech FBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.04K | Buy |
+994
| New | +$2.56K | ﹤0.01% | 4829 |
|
|
2023
Q3 | – | Sell |
-16
| Closed | -$136 | – | 4628 |
|
|
2023
Q2 | $136 | Buy |
+16
| New | +$158 | ﹤0.01% | 4431 |
|
|
2022
Q2 | – | Sell |
-794
| Closed | -$17K | – | 5095 |
|
|
2022
Q1 | $17K | Sell |
794
-5,229
| -87% | -$143K | ﹤0.01% | 4482 |
|
|
2021
Q4 | $226K | Buy |
6,023
+3,732
| +163% | +$166K | ﹤0.01% | 3520 |
|
|
2021
Q3 | $110K | Buy |
2,291
+1,687
| +279% | +$82.4K | ﹤0.01% | 3871 |
|
|
2021
Q2 | $32K | Sell |
604
-3,122
| -84% | -$188K | ﹤0.01% | 4331 |
|
|
2021
Q1 | $198K | Buy |
3,726
+2,287
| +159% | +$129K | ﹤0.01% | 3703 |
|
|
2020
Q4 | $68K | Sell |
1,439
-475
| -25% | -$20.6K | ﹤0.01% | 4289 |
|
|
2020
Q3 | $116K | Sell |
1,914
-204
| -10% | -$10.4K | ﹤0.01% | 4163 |
|
|
2020
Q2 | $85K | Buy |
+2,118
| New | +$78.7K | ﹤0.01% | 4620 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6224 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6473 |
|
|
2019
Q3 | – | Sell |
-179
| Closed | -$4K | – | 6818 |
|
|
2019
Q2 | $4K | Sell |
179
-508
| -74% | -$13.1K | ﹤0.01% | 6716 |
|
|
2019
Q1 | $18K | Buy |
+687
| New | +$18K | ﹤0.01% | 6389 |
|
|
2018
Q4 | – | Sell |
-874
| Closed | -$21K | – | 7043 |
|
|
2018
Q3 | $21K | Buy |
874
+708
| +427% | +$22.7K | ﹤0.01% | 6453 |
|
|
2018
Q2 | $7K | Sell |
166
-368
| -69% | -$20.7K | ﹤0.01% | 6633 |
|
|
2018
Q1 | $37K | Buy |
534
+185
| +53% | +$11.7K | ﹤0.01% | 6109 |
|
|
2017
Q4 | $21K | Buy |
349
+298
| +584% | +$17.6K | ﹤0.01% | 6261 |
|
|
2017
Q3 | $3K | Buy |
51
+49
| +2,450% | +$3.3K | ﹤0.01% | 6574 |
|
|
2017
Q2 | $0 | Sell |
2
-397
| -99% | -$23.4K | ﹤0.01% | 6723 |
|
|
2017
Q1 | $22K | Buy |
399
+333
| +505% | +$14.9K | ﹤0.01% | 5764 |
|
|
2016
Q4 | $2K | Buy |
66
+52
| +371% | +$1.94K | ﹤0.01% | 6343 |
|
|
2016
Q3 | $1K | Buy |
+14
| New | +$595 | ﹤0.01% | 6385 |
|
|
2015
Q1 | – | Sell |
-1,934
| Closed | -$58K | – | 7125 |
|
|
2014
Q4 | $58K | Sell |
1,934
-4,650
| -71% | -$137K | ﹤0.01% | 5603 |
|
|
2014
Q3 | $198K | Sell |
6,584
-725
| -10% | -$19.3K | ﹤0.01% | 4751 |
|
|
2014
Q2 | $110K | Buy |
7,309
+646
| +10% | +$17K | ﹤0.01% | 5338 |
|
|
2014
Q1 | $100K | Buy |
6,663
+26
| +0.4% | +$1.01K | ﹤0.01% | 5452 |
|
|
2013
Q4 | $199K | Buy |
6,637
+5,772
| +667% | +$223K | ﹤0.01% | 5018 |
|
|
2013
Q3 | $90K | Sell |
865
-680
| -44% | -$83.4K | ﹤0.01% | 5691 |
|
|
2013
Q2 | $200K | Buy |
+1,545
| New | +$228K | ﹤0.01% | 5172 |
|
Other funds holding FBIO
OM
GCP
SAM
BCM
Barclays's FBIO Position: Q2 2026 in Review
Barclays opened a new position in Fortress Biotech (FBIO) in Q2 2026: 994 shares worth $3.04K. The stake represents ﹤0.01% of the portfolio and ranks #4829 among its holdings. This is a return to the name: Barclays previously reported a position in FBIO as recently as Q2 2023.
Barclays first reported a position in FBIO in Q2 2013 and has held it in 28 quarters since. The position peaked at $226K in Q4 2021. 55 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.
- Barclays held 994 shares of Fortress Biotech worth $3.04K as of Q2 2026.
- Fortress Biotech was a new Barclays position in Q2 2026.
- Fortress Biotech made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4829 holding.
- Barclays first reported a position in Fortress Biotech in Q2 2013 and has held it in 28 quarters since.
- Barclays's Fortress Biotech position peaked at $226K in Q4 2021.
- 55 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.